Abstract
Hepatitis C virus (HCV) accounts for the majority of cases of transfusion acquired hepatitis and hepatitis transmitted by injecting drug use. The patients who do not clear the infection become chronic carriers of HCV and form a reservoir of infection within human populations. Furthermore, these carriers are at serious risk of developing cirrhosis of the liver and hepatocellular carcinoma. The disease is of major concern in developing as well as in developed countries and yet there are no vaccines against HCV, treatment is confined to the use of chemotherapy which is expensive and not always effective. The major obstacle in vaccine development is a limited understanding of the type of immune response that is necessary for viral clearance and the occurrence of various genotypes and quasispecies of HCV. The problems are further compounded by difficulties in growing the virus in vitro and the lack of a suitable and economical animal model. In this review we describe the virus, the strategies that it uses to evade the immune response and the tactics that may be useful in designing successful vaccine candidates.
Keywords: Hepatitis, immune response, quasispecies, chemotherapy
Current Drug Targets
Title: Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy
Volume: 5 Issue: 1
Author(s): Joseph Torresi, Mandvi Bharadwaj, David C. Jackson and Eric J. Gowans
Affiliation:
Keywords: Hepatitis, immune response, quasispecies, chemotherapy
Abstract: Hepatitis C virus (HCV) accounts for the majority of cases of transfusion acquired hepatitis and hepatitis transmitted by injecting drug use. The patients who do not clear the infection become chronic carriers of HCV and form a reservoir of infection within human populations. Furthermore, these carriers are at serious risk of developing cirrhosis of the liver and hepatocellular carcinoma. The disease is of major concern in developing as well as in developed countries and yet there are no vaccines against HCV, treatment is confined to the use of chemotherapy which is expensive and not always effective. The major obstacle in vaccine development is a limited understanding of the type of immune response that is necessary for viral clearance and the occurrence of various genotypes and quasispecies of HCV. The problems are further compounded by difficulties in growing the virus in vitro and the lack of a suitable and economical animal model. In this review we describe the virus, the strategies that it uses to evade the immune response and the tactics that may be useful in designing successful vaccine candidates.
Export Options
About this article
Cite this article as:
Torresi Joseph, Bharadwaj Mandvi, Jackson C. David and Gowans J. Eric, Neutralising Antibody, CTL and Dendritic Cell Responses to Hepatitis C Virus: A Preventative Vaccine Strategy, Current Drug Targets 2004; 5 (1) . https://dx.doi.org/10.2174/1389450043490677
DOI https://dx.doi.org/10.2174/1389450043490677 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Non-Integrating Lentiviral Vectors
Current Gene Therapy Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Zebrafish as a Model System to Screen Radiation Modifiers
Current Genomics Design, Synthesis and in vitro Cytotoxicity Evaluation of New 3',4'-bis (3,4,5-trisubstituted)-4'H-spiro[indene-2,5'-isoxazol]-1(3H)-one Derivatives as Promising Anticancer Agents
Letters in Drug Design & Discovery Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Leuckart Synthesis and Pharmacological Assessment of Novel Acetamide Derivatives
Anti-Cancer Agents in Medicinal Chemistry Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Apoptosis and Autophagy Induction As Mechanism of Cancer Prevention by Naturally Occurring Dietary Agents
Current Drug Targets CXCR4 Receptor as a Promising Target for Oncolytic Drugs
Mini-Reviews in Medicinal Chemistry MicroRNAs in Breast Cancer: One More Turn in Regulation
Current Drug Targets Pharmacological Exploitation of Indole-3-Carbinol to Develop Potent Antitumor Agents
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic: Lipids in Cancer Cell Biology and Therapy Guest Editor: Jose C. Fernandez-Checa)]
Anti-Cancer Agents in Medicinal Chemistry Extracellular Ca<sup>2+</sup> Selectively Enhances Adriamycin-induced Cell Death in Human Hepatoma Cells
Current Cancer Drug Targets Infection, Stem Cells and Cancer Signals
Current Pharmaceutical Biotechnology Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors
Anti-Cancer Agents in Medicinal Chemistry